GlassScriptPhysician profile
Abbas El-Khatib
NPI 1386709970
$2,728.98
in general payments reported to CMS, 2019-2025
16 companies · $69.37 in 2025
The $69.37 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $45.00 · 2021: $195 · 2022: $702 · 2023: $1,023 · 2024: $561 · 2025: $69.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $657.14 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $569.26 | 2022-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $361.90 | 2021-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.25 | 2022-2024 | Jardiance |
| Vifor Pharma, INC. | $196.47 | 2019-2022 | |
| Travere Therapeutics, INC. | $186.83 | 2023-2024 | |
| Nxstage Medical, INC. | $137.58 | 2020-2023 | Liberty Select Cycler, Nxstage System One |
| Pfizer INC. | $73.38 | 2019 | |
| Novo Nordisk INC | $73.25 | 2023 | Wegovy |
| Fresenius USA Marketing, INC. | $70.70 | 2023 | Korsuva, Velphoro |
| Opko Pharmaceuticals, LLC | $49.48 | 2022 | |
| Glaxosmithkline, LLC. | $47.83 | 2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $42.02 | 2024 | |
| Alnylam Pharmaceuticals INC. | $26.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.75 | 2023 | Keveyis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas El-Khatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.